Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic

Executive Summary

The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.

Advertisement

Related Content

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
Amgen Will Try To Convince ODAC Of Minimal Disease Endpoint To Show Blincyto's Efficacy
Amgen, Merck To Test New Immunotherapy Combination
Amgen gains early US win for BiTE antibody Blincyto
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100484

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel